Abstract
Purpose
We aim to delineate the clinical characteristics of patients with primary intracranial solitary plasmacytoma (PISPC) and prognostic factors for their outcomes.
Methods
This study retrospectively reviewed 17 patients with PISPC from our center and an additional 70 cases of PISPC published previously to analyze outcome predictors.
Results
The entire cohort included 38 (43.7%) males and 49 (56.3%) females with a mean age of 54 years. Skull base tumors were found in 49 (56.3%) patients. Gross total resection (GTR) was achieved in 31 (35.6%) patients. Postoperative adjuvant treatments, including radiotherapy (RT) alone, chemotherapy (CMT) alone, and RT + CMT were administered in 49 (56.3%) patients, 3 (3.5%) patients, and 16 (18.4%) patients, respectively. After a median follow-up of 24 (mean 42.4) months, the 5-year disease progression-free survival (PFS), recurrence-free survival (RFS), multiple myeloma (MM)-free survival (MMFS), and overall survival (OS) were 52.9%, 76.2%, 69.6%, and 76.1%, respectively. Multivariate analysis unveiled that a skull base tumor location (HR 2.395, p = 0.040) and no RT (HR 3.115, p = 0.004) were negative prognostic factors for PFS, no RT (HR 10.526, p = 0.003) for RFS, each 1-year increase in age (HR 1.039, p = 0.049) for MMFS, and increasing age (HR 1.052, p = 0.043) and CMT (HR 6.022, p = 0.005) were risk factors for OS. However, GTR did not benefit the aforementioned outcomes.
Conclusion
For patients with presumed PISPC, a biopsy followed by RT is recommended for skull base PISPC. However, the role of CMT is still not clear. Our findings need to be verified in a larger prospective cohort in the future. Systematic review registration number CRD42018098782.
Similar content being viewed by others
Change history
25 January 2019
The article Clinical features, radiological profiles, and surgical outcomes of primary intracranial solitary plasmacytomas: a report of 17 cases and a pooled analysis of individual patient data, written by Xiu-Jian Ma, Da Li, Liang Wang, Shu-Yu Hao, Li-Wei Zhang, Jun-Ting Zhang, Zhen Wu, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 7 January 2019 with open access. With the authors’ decision to step back from Open Choice, the copyright of the article changed on 25 January 2019 to © Springer Science + Business Media, LLC, part of Springer Nature 2019 and the article is forthwith distributed under the terms of copyright.
Abbreviations
- CI:
-
Confidence interval
- CMT:
-
Chemotherapy
- GTR:
-
Gross total resection
- HR:
-
Hazard ratio
- NGTR:
-
Nongross total resection
- OS:
-
Overall survival
- PISPC:
-
Primary intracranial solitary plasmacytoma
- RT:
-
Radiotherapy
- SPC:
-
Solitary plasmacytoma
References
Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D, Guidelines Working Group of the UKMF, British Committee for Standards in H, British Society for H (2004) Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 124 (6):717–726. https://doi.org/10.1016/j.clon.2004.02.007
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ (2016) Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol 91(6):575–580. https://doi.org/10.1002/ajh.24351
Schwartz TH, Rhiew R, Isaacson SR, Orazi A, Bruce JN (2001) Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study. Neurosurgery 49(5):1039
Mclaughlin DM, Gray WJ, Jones FG, Mirakhur M, Mccance DR, Sheridan B, Atkinson AB (2004) Plasmacytoma: an unusual cause of a pituitary mass lesion. A case report and a review of the literature. Pituitary 7(3):179–181
Mandagere KA, Schimke RN, Kyner JL, Bhatia PS (1998) An unusual sellar mass–solitary plasmacytoma. Endoc Pract 4(6):382
Pritchard PB 3rd, Martinez RA, Hungerford GD, Powers JM, Perot PL Jr (1983) Dural plasmacytoma. Neurosurgery 12(5):576–579
Bindal AK, Bindal RK, van Loveren H, Sawaya R (1995) Management of intracranial plasmacytoma. J Neurosurg 83(2):218–221. https://doi.org/10.3171/jns.1995.83.2.0218
Gagliardi F, Losa M, Boari N, Spina A, Reni M, Terreni MR, Mortini P (2013) Solitary clival plasmocytomas: misleading clinical and radiological features of a rare pathology with a specific biological behaviour. Acta Neurochir 155(10):1849–1856. https://doi.org/10.1007/s00701-013-1845-3
Lee J, Kulubya E, Pressman BD, Mamelak A, Bannykh S, Zada G, Cooper O (2017) Sellar and clival plasmacytomas: case series of 5 patients with systematic review of 65 published cases. Pituitary 20(3):381–392. https://doi.org/10.1007/s11102-017-0799-5
Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, Patriarca F, Nozzoli C, Cavo M, Offidani M, Floridia M, Berretta S, Vallone R, Musto P, Lauria F, Party GMW, Marchini E, Fabbri A, Oliva S, Zamagni E, Sapienza FG, Ballanti S, Mele G, Galli M, Pirrotta MT, Di Raimondo F (2012) Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer 118(6):1574–1584. https://doi.org/10.1002/cncr.26447
Nieuwenhuizen L, Biesma DH (2010) Central nervous system myelomatosis: review of the literature. Eur J Haematol 80(1):1–9
Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Dincbas FO, Landmann C, Castelain B, Buijsen J, Curschmann J, Kadish SP, Kowalczyk A, Anacak Y, Hammer J, Nguyen TD, Studer G, Cooper R, Sengoz M, Scandolaro L, Zouhair A (2006) Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64(1):210–217. https://doi.org/10.1016/j.ijrobp.2005.06.039
Schwartz TH, Rhiew R, Isaacson SR, Orazi A, Bruce JN (2001) Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study. Neurosurgery 49(5):1039–1044. https://doi.org/10.1097/00006123-200111000-00002 (discussion 1044–1035).
Liu ZY, Qi XQ, Wu XJ, Luo C, Lu YC (2010) Solitary intracranial plasmacytoma located in the spheno-clival region mimicking chordoma: a case report. J Int Med Res 38(5):1868–1875. https://doi.org/10.1177/147323001003800535
Na’ara S, Amit M, Gil Z, Billan S (2016) Plasmacytoma of the skull base: a meta-analysis. J Neurol Surg Part B 77(1):61–65. https://doi.org/10.1055/s-0035-1560047
Ferreira-Filho LA, Pedroso JL, Sato EA, Yared JH, Barsottini OG, Bulle Oliveira AS, Diniz-Ferreira NP (2014) Teaching neuroimages: “mini brain” sign: a radiologic marker for vertebral solitary plasmacytoma. Neurology 82(23):e210–e211. https://doi.org/10.1212/WNL.0000000000000494
Provenzale JM, Schaefer P, Traweek ST, Ferry J, Moore JO, Friedman AH, McLendon RE (1997) Craniocerebral plasmacytoma: MR features. AJNR Am J Neuroradiol 18(2):389–392
Cerase A, Tarantino A, Gozzetti A, Muccio CF, Gennari P, Monti L, Di Blasi A, Venturi C (2008) Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology 50(8):665–674. https://doi.org/10.1007/s00234-008-0390-x
Juneau P, Schoene WC, Black P (1992) Malignant tumors in the pituitary gland. Arch Neurol 49(5):555–558. https://doi.org/10.1001/archneur.1992.00530290147025
Devoe CE, Li JY, Demopoulos AM (2014) The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide. J Neuro-oncol 119(1):217–220. https://doi.org/10.1007/s11060-014-1475-5
Krause S, Hillengass J, Goldschmidt H, Debus J, Neuhof D (2011) Radiotherapy of solitary plasmacytoma. Ann Hematol 90(9):1093–1097. https://doi.org/10.1007/s00277-011-1190-7
Finsinger P, Grammatico S, Chisini M, Piciocchi A, Foa R, Petrucci MT (2016) Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol 172(4):554–560. https://doi.org/10.1111/bjh.13870
Corwin J, Lindberg RD (1979) Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma. Cancer 43(3):1007–1013
Vengalathur RG, Kavindapadi KV, Chandramouli B (2014) Primary plasmacytoma of the anterior skull base: a rare case. Neurology India 62(5):545–546. https://doi.org/10.4103/0028-3886.144457
Rahman EZ, Barros Palau AE, Morgan ML, Lee AG (2016) Neuro-ophthalmic presentations of clival plasmacytoma. Can J Ophthalmol 51(2):e49–e53. https://doi.org/10.1016/j.jcjo.2015.10.017
Chim CS, Ooi GC (2005) Bulbar palsy in multiple myeloma. Haematologica 90(12 Suppl):ECR42
Holland J, Trenkner DA, Wasserman TH, Fineberg B (1992) Plasmacytoma. Treatment results and conversion to myeloma. Cancer 69 (6):1513–1517. https://doi.org/10.1002/1097-0142(19920315)69:6%3C1513::AID-CNCR2820690633%3E3.0.CO;2-X
Mancilla-Jimenez R, Tavassoli FA (1976) Solitary meningeal plasmacytoma: report of a case with electron microscopic and immunohistologic observations. Cancer 38(2):798–806
Aviles A, Huerta-Guzman J, Delgado S, Fernandez A, Diaz-Maqueo JC (1996) Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 14 (3):111–117. https://doi.org/10.1002/(SICI)1099-1069(199609)14:3%3C111::AID-HON575%3E3.0.CO;2-G
Vujovic O, Fisher BJ, Munoz DG (1998) Solitary intracranial plasmacytoma: case report and review of management. J Neuro-oncol 39(1):47–50. https://doi.org/10.1023/A:1005987120570
Ferrari S, Tecchio C, Turri G, Richelli S, Ghimenton C, Monaco S, Todeschini G (2012) Unusual case of solitary intraparenchymal brain plasmacytoma. J Clin Oncol 30(33):e350–e352. https://doi.org/10.1200/JCO.2012.43.0215
Krumholz A, Weiss HD, Jiji VH, Bakal D, Kirsh MB (1982) Solitary intracranial plasmacytoma: two patients with extended follow-up. Ann Neurol 11(5):529–532. https://doi.org/10.1002/ana.410110514
Mussetti A, Dalto S, Montefusco V (2013) Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma 54(4):864–866. https://doi.org/10.3109/10428194.2012.718343
Acknowledgements
This work was supported in part by the Natural Science Foundation of China (Grant No.81672506 to Z.W. and 814742370 to J.T.Z.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors declared that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
The original version of this article was revised: With the authors’ decision to step back from Open Choice, the copyright of the article changed on 25 January 2019 to © Springer Science+Business Media, LLC, part of Springer Nature 2019 and the article is forthwith distributed under the terms of copyright.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ma, XJ., Li, D., Wang, L. et al. Clinical features, radiological profiles, and surgical outcomes of primary intracranial solitary plasmacytomas: a report of 17 cases and a pooled analysis of individual patient data. J Neurooncol 142, 263–272 (2019). https://doi.org/10.1007/s11060-019-03089-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-019-03089-z